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John W. Ward,1 Anna S.F. Lok,2 David L. Thomas,3 Hashem B. El-Serag,4 and W. Ray Kim5
The 2010 Institute of Medicine report on ‘‘Hepatitis and Liver Cancer’’ indicated that lack
of knowledge and awareness about chronic hepatitis B (HBV) and C virus (HCV) infec-
tions and insufﬁcient understanding about the extent and seriousness of this public health
problem impeded current efforts to prevent and control hepatitis B and C. A single-topic
conference was held in June 2011 to discuss strategies to improve the effectiveness of
screening, care referral, and clinical management of chronic HBV and HCV infections
with the ultimate goal of reducing morbidity and mortality from these infections. Various
models that have been shown to improve hepatitis screening and effectiveness of hepatitis
treatment in the community, including rural settings and populations that have tradition-
ally been excluded due to comorbidities, were presented. Recent advances in laboratory
testing, medical management, and new antiviral therapies will not decrease the burden of
viral hepatitis if persons at risk for or who are living with viral hepatitis are not aware of
the risks, have not been diagnosed, or have no access to care. Systematic changes in our
health care delivery system and enhanced coordination of prevention and care services
with partnerships between public health leaders and clinicians through education of the
public and health care providers and linkage of infected persons with care and treatment
services can increase the success of preventing viral hepatitis and the effectiveness of hepa-
titis treatment in the real world. Implementation of these changes is feasible and will
require policy changes, coordination among government agencies, and collaboration
between government agencies, health care providers, community organizations, and advo-
cacy groups. (HEPATOLOGY 2012;55:307-315)
I
n January 2010, the Institute of Medicine (IOM)
issued a report on hepatitis and liver cancer.1 The
IOM review committee estimated that 3.5 million
to 5.3 million persons in the United States are living
with chronic hepatitis B virus (HBV) or chronic hepa-
titis C virus (HCV) infections and an estimated
150,000 persons will die from liver cancer or end-stage
liver disease associated with chronic hepatitis B and
hepatitis C. The committee found that lack of knowl-
edge and awareness about chronic viral hepatitis on
the part of health care and social service providers, and
insufﬁcient understanding about the extent and seri-
ousness of this public health problem, impede current
efforts to prevent and control hepatitis B and C.
A single-topic conference, cosponsored by the Ameri-
can Association for the Study of Liver Diseases
(AASLD) and the Centers for Disease Control and Pre-
vention (CDC), was held on June 4-5, 2011 (http://
www.multiwebcast.com/aasld/2011/cdc.aasld.stc.hepatitis/)
to discuss strategies to improve the effectiveness of
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screening, care referral, and clinical management of
chronic HBV and chronic HCV infections with the ulti-
mate goal of reducing morbidity and mortality from
chronic HBV and chronic HCV infection.
Session I: Disease Burden, Epidemiology,
Economics, and Opportunities to Prevent
and Treat Viral Hepatitis
(HaroldW. Ja¡e, JohnW.Ward,W.Ray
Kim,Marc G.Ghany, JohnB.Wong)
Based on the National Health and Nutrition Exami-
nation Survey (NHANES), an estimated 1%-2% of
the US population is chronically infected with HBV or
HCV.2,3 The annual direct medical care costs of HBV
infection have been estimated to be US $205 million
to US $1.2 billion and that of HCV infection is esti-
mated at US $1.1 billion. The annual indirect medical
care costs related to premature mortality and disability
of those age <65 years with chronic HCV infection
have been estimated to be US $7.5 billion.
Data from NHANES (1999-2008) estimated that
only 0.27% of the US general population aged 6
years had chronic HBV infection.3 However, screening
studies conducted among Asian Americans revealed a
prevalence of 10%-15%, and a recent study of African
refugees living in Atlanta, GA, found a prevalence of
11%. Estimates based on immigration data project
that of 41 million foreign-born individuals living in
the United States as of 2008; there were approximately
1.5 million with chronic HBV infection, most of
whom were from Asia, followed by Central America
and Africa.4 Vaccination can prevent HBV infection,
and HBV vaccine is recommended for all children be-
ginning at birth and for adults who are at risk for
infection. Nevertheless, a recent survey found that only
61% of newborns had received the ﬁrst dose of HBV
vaccine and only 45% of adults with high-risk behav-
iors had been vaccinated.5,6
NHANES IV (1999-2002) estimated that 1.3% of the
noninstitutionalized civilian US population had chronic
HCV infection, but several groups such as the homeless
or the incarcerated with prevalence up to 40% were not
included in the survey.2 Among those surveyed, preva-
lence was higher in blacks (3.0%) and those who were
40-49 years old (4.3%). Two-thirds of those who were
infected were born in 1945-1964. The cohort effect is
presumably related to infection through injection drug
use (IDU) and health care exposures (e.g., unscreened
blood transfusions) in the 1960s to the 1980s. This
ﬁnding implies that the proportion of patients with
HCV who have had the infection long enough to have
progressed to cirrhosis and hepatocellular carcinoma
(HCC) is increasing. Indeed, age-adjusted mortality
from chronic HCV infection and incidence of HCC
has continued to increase (Fig. 1).7,8 Furthermore, fol-
lowing a period of decline in incidence of HCV infec-
tion, there is a resurgence of HCV infection, mainly
among young injection drug users.9
HBV and HCV screening of at-risk groups is the
ﬁrst step toward care of the infected person and pre-
vention of transmission to others. Yet, a review of
records in four medical clinics in the United States
found that only approximately 20% of patients had
ever been tested for hepatitis B, and only half of those
who are expected to be infected with hepatitis C had
been diagnosed. Data from randomized controlled
trials, cohort studies, and meta-analyses support that
antiviral treatment can decrease disease progression
particularly among responders. Improved diagnosis,
referral, and access to care are needed in order for per-
sons who are chronically infected with HBV or HCV
to have an opportunity to beneﬁt from treatment. Eco-
nomic evaluations suggest that HBV and HCV treat-
ments are cost-effective.10 HBV treatment needs to be
administered for many years, and further research is
needed to determine the optimal time to start treat-
ment and the most cost-effective strategy. New HCV
treatment with direct-acting antivirals costs more, but
this may be offset by a higher rate of response and/or
a shorter duration of treatment.
In response to the IOM report, several public policy
developments have been initiated. In September 2010,
the Trust for America’s Health and AASLD released an
issue brief that laid out the challenges presented by
viral hepatitis and concrete policy prescriptions for
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dealing with those challenges.11 In May 2011, the US
Department of Health and Human Services (HHS)
issued ‘‘Combating the Silent Epidemic: Action for the
Prevention, Care, and Treatment of Viral Hepatitis’’,12 a
road map for the nation’s public health response to
viral hepatitis (Table 1).
Session II: Education and Community
Engagement: Improving the Demand
and Acceptance of Viral Hepatitis
Prevention and Care Services
(Cynthia Jorgensen,SamuelK. So,Charles
D.Howell,BruceE.Landon,Fasiha
Kanwal)
A major hurdle in hepatitis prevention and control
in the United States is the lack of public and provider
awareness, which has led to inadequate public health
and health care resource allocation. A recent CDC
study showed that both awareness and knowledge of
viral hepatitis were extremely low among the public
at large, as well as among speciﬁc subgroups such as
African Americans and Asian Americans. Little was
known about the different types, risk factors, and route
of transmission of viral hepatitis. Participants were
unaware of the asymptomatic nature and hence the
need for speciﬁc testing for hepatitis virus infection.
These data highlight the critical need for educational
efforts to improve public knowledge of viral hepatitis.
African Americans and Asian Americans represent
two ethnic groups in whom public health and educa-
tional efforts are most needed, given the dispropor-
tionate burden of viral hepatitis among them. Both
groups have higher age-adjusted mortality rates from
cirrhosis and HCC than do non-Hispanic whites. One
potential reason for the bigger impact of viral hepatitis
among African Americans is limited access to health
care. The problem is compounded by the lower
response rates to antiviral therapy for HCV among
African Americans, a difference that is in part genetic
(i.e., interleukin-28B)13 and not overcome by the
newly approved protease inhibitors.14,15 With regard
to HBV, the highest burden is among Asian Ameri-
cans, yet awareness is low. Liver cancer is the second
most common cancer among Asian American men,
whereas it is the ninth most common among non-
Hispanic white men. Reaching Asian Americans for
public awareness education on HBV is challenging,
because they represent a diverse group with different
languages and cultures and include a high proportion of
foreign-born individuals with low English proﬁciency.
As of 2011, eliminating racial disparities in viral
hepatitis remains a substantial challenge. Grassroots
efforts have been organized by Asian American advo-
cacy groups, which have motivated a small number of
local and federal government agencies to engage in
Fig. 1. Crude prevalence of cir-
rhosis, decompensated cirrhosis, and
HCC. Data were derived from a
national sample of veterans with hep-
atitis C that increased from 17,261 in
1996 to 106,242 in 2006.8
Table 1. Proposed 2020 Goals of Health and Human
Services Action Plan to Combat Viral Hepatitis
 Increase from 33% to 66% the proportion of persons who are aware of their
HBV infection
 Increase from 45% to 66% the proportion of persons who are aware of their
HCV infection
 Reduce by 25% the number of new HCV infections
 Eliminate mother-to-child HBV transmission
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public health campaigns.16 These programs have
focused on education of the public, hepatitis testing of
those who have not been screened, vaccination of
persons at risk for HBV infection as indicated, and
clinical monitoring with preventive and therapeutic
interventions in those who are infected. For HCV,
proposals have been put forth to refocus screening
strategies so that it is guided by demographic charac-
teristics rather than risk behavior.
Although these efforts represent an encouraging
recent trend, more fundamental changes at the health
care system level is necessary to substantively alter the
burden and improve clinical outcomes of viral hepatitis
at the national level. These systematic changes may
include reengineered care processes, effective use of in-
formation technology, implementation of knowledge/
skills management, development of health care teams,
and coordination of care.17 This model emphasizes the
shared responsibility among public health and primary
and specialty care providers in addressing viral hepatitis
(Fig. 2). Implementation of such coordination may be
facilitated by systematic improvements such as effective
application of information technology and use of per-
formance measurement to gauge and improve perform-
ance and to track progress at each level of the system.
Physicians and other providers are a key component
of the health care system. Motivating them to improve
quality of care requires a multifaceted approach which
may include self-directed or mandated learning as well
as direct and indirect ﬁnancial incentives. These con-
siderations have increasingly been applied in HCV at
the federal government level. The Centers for Medi-
care and Medicaid Services (CMS) has recognized
HCV as a priority area for quality measurement18
(Table 2). Quality measures are thought to be a prel-
ude to the pay-for-performance (P4P) model in which
payment incentives are used to recognize and reward
high-quality care and quality improvement. P4P has
been shown to produce intended results in some areas
of medicine, but the impact of the HCV program
remains to be seen. At present, a parallel strategy has
not been developed for HBV.
Session III: Screening and Care Referral
for Chronic HBV and Chronic HCV: The
Entry Point for Counseling and Care
(Alain Litwin,KarenE.Kim,Trudy V.Murphy,
Daniel Church,Bryce Smith, Je¡rey Levi)
It is estimated that 75% of persons with chronic
HCV infection in the United States are unaware that
they are infected. In 1998, the CDC recommended
anti-HCV testing for high-risk populations; however,
barriers to risk assessments including reluctance of pro-
viders to ask patients sensitive questions and patient
reticence to disclose risk behaviors resulted in very low
rate of identiﬁcation of at-risk persons and subsequent
HCV screening.19
Screening for HBV is effective in reducing the burden
of disease, preventing disease transmission, and providing
an opportunity for treatment and HCC surveillance.
Many screening programs have been developed and
initiated as community-based programs, but they do
not provide adequate linkage to care or follow-up for
at-risk individuals. In the United States, screening for
chronic HBV infection is recommended for all preg-
nant women, and high rates of screening has been
achieved. However, a survey of 190 birthing hospitals
in 2005 found that <73% of hospitals had policies for
reviewing the pregnant woman’s hepatitis B surface
antigen (HBsAg) test result on admission for delivery,
or policies to test pregnant women on admission if no
documented HBsAg test result is available.20 Modeling
estimates suggest a trend toward an increasing number
of infants in the United States born to HBsAg-positive
mothers, most of whom came from countries with
Fig. 2. Overlapping spheres of responsibilities. In order to compre-
hensively address viral hepatitis in a systematic fashion, concerted
efforts are necessary by providers of public health, primary care, and
specialty care for viral hepatitis.
Table 2. Medicare Quality Indicators for Hepatitis C
If— Then— Evidence (Grade)
Positive anti-HCV HCV RNA test II-2
Positive HCV RNA HCV treatment I
If HCV treatment Genotype test I
If HCV treatment Viral load pretreatment I
If HCV treatment Viral load at week 12* I
Positive HCV test Hepatitis A vaccination II-2
Positive HCV test Hepatitis B vaccination III
*Indicators for peginterferon and ribavirin treatment.
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intermediate or high prevalence of chronic HBV infec-
tion.21 For 2007, the estimate was >25,000 infants, a
signiﬁcant increase from 19,000 in 1993.
In order to overcome the barriers in screening for
viral hepatitis, there may need to be systematic integra-
tion of screening in clinical and public health settings,
as well as policy changes.
Several approaches to increasing referral and screen-
ing for HCV have been shown to be effective, such as
the use of brief HCV risk screeners, electronic medical
records, and a database risk algorithm.22 In clinical set-
tings with a high prevalence of infection (e.g., metha-
done clinics), a universal testing strategy can be used.
In primary care clinics, both risk-based screener sticker
and birth cohort sticker, which prompts physicians to
order HCV tests on patients with risk factors and all
patients born within a high-prevalence birth cohort
(1945-1964), were associated with a high yield of
identifying those who test positive (>5%).23 A good
model is the Veterans Administration (VA) HCV pro-
gram, which integrates HCV screening within routine
clinical care. More than 95% of people who come
into the VA system for care have been screened for
risk factors, and more than 90% of those found to be
at risk have been tested for HCV.
There are also several potentially effective
approaches to referral: (1) Self-referral, which may
help to overcome the barriers of lack of access to pri-
mary care providers; (2) HCV case managers and
patient navigators who can serve as an important link
between patient and medical staff to facilitate appro-
priate and timely referrals and to connect participants
to resources that strengthen commitment to initiate
and complete antiviral treatment; (3) telemedicine,
such as the project Extension for Community Health-
care outcomes (ECHO), a telemedicine and distance-
learning program, demonstrates that specialty care can
be extended to remote areas;24 and (4) Colocated HCV
screening, testing, and treatment services. Many success-
ful integrated models of HCV screening and treatment
have been described within primary care settings, sub-
stance abuse treatment settings, human immunodeﬁ-
ciency virus (HIV) clinics, liver clinics partnering with
methadone clinics, and correctional settings.25,26
The 2010 IOM report1 recommended that the
CDC work with state and other local partners to fund
comprehensive care for persons at risk for, or infected
with, HBV and/or HCV. Correctional services, sexually
transmitted disease (STD)/HIV clinics, and mobile
health units were identiﬁed as appropriate settings for
this type of integrated approach. Viral hepatitis screen-
ing can be increased through a variety of approaches
that harness existing resources within the public health
system more effectively. These approaches include pol-
icy opportunities for CMS to assure broader screening,
reassessment of screening policies by the US Preventive
Services Task Force, inclusion of HBV/HCV screening
as part of the essential health beneﬁts deﬁned by the
Secretary for the health insurance exchanges, and
expansion of Health Resources and Services Adminis-
tration (HRSA) screening efforts at their funded sites
such as Community Health Centers and Ryan White
HIV clinics. Although each of these strategies will
require signiﬁcant policy changes, they can be imple-
mented within existing budgetary constraints or incor-
porated under the Affordable Care Act.
The CDC is evaluating an expansion in HCV
screening policy from risk-based to a one-time screen-
ing of all persons born from 1945-1965. This strategy
circumvents the limitations of risk-based approaches
by not requiring the discussion of sensitive behaviors.
Session IV: Models of Care for Chronic
Viral Hepatitis
(RonaldO.Valdiserri,BrianR.Edlin, Janet
M.Durfee,SanjeevArora,Shruti H.Mehta,
SuH.Wang)
The HHS Action Plan for the Prevention of Vi-
ral Hepatitis12 has four goals (Table 1). To achieve
these goals, the plan speciﬁcally targets the follow-
ing: education of providers and communities;
expansion of testing, care, and treatment; intensiﬁ-
cation of surveillance; elimination of vaccine-pre-
ventable hepatitis (in particular, mother-to-child
transmission of HBV); reduction of hepatitis associ-
ated with illicit drug use; and prevention of health
care–associated hepatitis.
Achieving the goals of the Action Plan will require
improved coordination at all levels of government
and the full engagement of health professionals, com-
munities, and private sector partners. The plan com-
mits no additional resources; however, improved pri-
ority setting and coordination across federal health
programs together with implementation of the
Affordable Care Act will address many current unmet
needs by offering new opportunities to promote dis-
ease prevention and access to quality care for persons
with viral hepatitis.
Because the majority of HCV infections in the
United States were acquired through IDU, efforts to
combat chronic liver disease must comprehensively
address that population. Nonetheless, there are numer-
ous challenges. Patients suffer a disproportionate
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burden of poverty, homelessness, mental illness, stig-
matization, and competing priorities. Physicians who
have experience treating HCV infection may not be
sufﬁciently experienced in delivering care to IDUs and
vice versa. At the level of health care services, chal-
lenges include fragmentation of substance abuse treat-
ment and other medical care, lack of health insurance,
transportation, and even identiﬁcation of infection
through testing and counseling.
To overcome these challenges, innovative health care
delivery models have been tested such as the Multidisci-
plinary Integrated Care Program for Substance Using Per-
sons in New York. For persons actively using illicit drugs
the program brings together persons with experience in
substance abuse and HCV treatment and addresses com-
mon concurrent conditions like mental illness.
The VA also has tested models for delivering care
for the estimated 165,000 veterans in care with HCV
infection. Approximately 14% of HCV-infected veter-
ans are known to have cirrhosis, and there has been a
steady increase in the number with HCC and/or liver-
related deaths; however, only 23% of veterans with
HCV report having ever been treated, and reasons for
not providing treatment include psychiatric disease,
substance abuse, advanced liver disease, comorbid dis-
ease, and patient issues.27 Patients who had integrated
psychiatric and medical care were more likely to com-
plete evaluation for and to start HCV treatment than
other patients with mental health issues.28 The VA
remains a model for what could be possible with a
national health plan.
An innovative statewide program for delivery of
HCV care in New Mexico used a disease management
model via telemedicine. Health care workers in 21
rural clinics were trained, and the SVR rates to HCV
treatment in these clinics were comparable to that
achieved by patients treated at the University of New
Mexico clinic.29
To respond to the large number of foreign-born per-
sons with chronic hepatitis B in New York, NY, inno-
vative programs have been implemented at the Charles
B. Wang Community Health Center. More than 8900
persons were screened for HBV infection between
2004 and 2009, and 11.7% were found to be positive
for HBsAg for the ﬁrst time. Using a chronic care
model that includes an integrated electronic medical
record, a cohort of 4500 persons with chronic HBV
infection is followed. A special program targets preg-
nant women to prevent mother-to-infant transmission
of HBV. Coordination of care is greatly enhanced by
an electronic medical record that provides reminders
for key elements of monitoring and treatment.
It is also instructive to consider how models of care
used for HIV and other chronic medical conditions
might inform the response to viral hepatitis. Much of
the HIV care in the United States is delivered in dedi-
cated treatment centers. Funded by HRSA through the
Ryan White Care Act, these clinics are able to deliver
comprehensive services that include primary care as
well as substance abuse care, mental health care, social
services, palliative care, and pharmaceutical assis-
tance.30 Teams of health care workers deliver the care
in patient-centered ‘‘medical homes’’ where HIV-
related mortality and morbidity has been substantially
reduced. Other strategies have also been tried, such as
traditional consultative models, remote consultative
services (hotlines via telephone), joint nurse practi-
tioner–physician teams, and integrating general medi-
cine or HIV treatment expertise into an existing
chronic care setting.31,32
Another model of care that has been applied to
other chronic conditions, and more recently to HIV, is
the Chronic Care Model, which recognizes that health
efforts must be distributed across the community,
patients, and health system (Fig. 3). A key emphasis is
on motivating patients to have a signiﬁcant role in
their own health care and keeping providers informed
with respect to guidelines.33
Session V: Standards of Viral Hepatitis
Care and Treatment—From Efﬁcacy
to Effectiveness
(Mark Sulkowski, Anna S.Lok,HashemB.
El-Serag, JohnW.Ward)
Advances in the treatment of chronic hepatitis B
and hepatitis C, along with surveillance for HCC can
improve patient outcomes. However, the efﬁcacy (i.e.,
interventions observed under carefully controlled con-
ditions) of therapeutic interventions and screening
demonstrated in clinical trials do not always reﬂect the
effectiveness (i.e., utility of an intervention in routine
clinical settings) of those interventions in routine
practice.
Seven therapies have been approved for treating
chronic hepatitis B. These treatments suppress HBV
replication and result in hepatitis B ‘‘e’’ antigen sero-
conversion, alanine aminotransferase normalization,
and histologic improvement in some patients.34
In May 2011, the ﬁrst generation of HCV nonstruc-
tural 3/4A protease inhibitors, Telaprevir and Boceprevir,
were licensed for clinical use in the United States. Com-
pared with peginterferon/ribavirin therapy alone, the
addition of Boceprevir or Telaprevir increased sustained
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viral response rates from 38% to 63% and 46% to
79%, respectively.14,15 Guided by patients’ on-treatment
HCV RNA level, treatment duration can be as short as
24-28 weeks for patients with rapid viral response.
Despite the proven efﬁcacy of hepatitis B and hepa-
titis C therapies, several factors limit the impact of
these advances on improving outcomes for persons in
routine clinical care, including the low percentage of
persons aware they are infected (approximately 35%
for HBV and as few as 25% for HCV); low rates of
referral to care and treatment (40% and 21% for
HBV and HCV infection, respectively)35,36; inadequate
number of clinicians trained to treat infected patients;
and high cost of therapy. As a result, of the 3.5 mil-
lion to 5.3 million persons chronically infected with
viral hepatitis in the United States, fewer than one in
ﬁve are receiving therapy that can potentially prevent
adverse clinical outcomes.35,37
Additional challenges hamper efforts to treat
patients with viral hepatitis. For instance, certain
HCV-infected patients are not candidates for the
newly available regimen and the potential for drug–
drug interactions and signiﬁcant adverse events may
compromise treatment outcomes. In addition, drug re-
sistance can diminish the efﬁcacy of treatment for
both hepatitis B and hepatitis C. The lengthy duration
of time required to treat viral hepatitis, particularly
hepatitis B, increases the likelihood of missed doses,
which can lead to viral mutations and diminished
response to available medications.
HCC is the fastest rising cause of cancer-related
death in the United States, where most HCC is caused
by chronic infection with HCV (47%), HBV (15%),
or both types of viral hepatitis (5%). Several studies
have demonstrated the efﬁcacy of periodic HCC screen-
ing to detect tumors at an earlier stage, increase the
likelihood that patients will receive potentially curative
therapy, and reduce cancer-speciﬁc mortality compared
with patients detected with symptomatic HCC. How-
ever, implementation of HCC screening in clinical prac-
tice is poor. In a recent study of 13,002 HCV-infected
veterans diagnosed with cirrhosis during 1998-2005,
<50% were screened for HCC within the ﬁrst year of
diagnosis, and only 12% received annual HCC screen-
ing during the 3 years following diagnosis.38
Action can be taken at the societal and provider
level to improve the effectiveness of viral hepatitis
treatment and HCC screening in clinical settings.
At the societal level, changes in health care policies
and reimbursement can increase access to viral hepati-
tis screening, care, and treatment, and community
education can motivate persons to seek recommended
prevention and care services. At the provider level, bet-
ter educating health professionals about recommenda-
tions for viral hepatitis testing and HCC screening,
and increasing their awareness of available therapeutic
options will improve testing and treatment rates, as
will use of clinical decision aids. Logistical barriers
(e.g., adherence to a protocol of multiple tests and
treatment over a prolonged period and access to
expensive therapy) also must be addressed to improve
the effectiveness of viral hepatitis-related testing and
treatment. Finally, research is needed to increase thera-
peutic options and identify those models of care that
will close the gap between results demonstrated in
clinical trials and those achieved in clinics across the
country. Table 3 summarizes key actions for physicians
and other health care providers toward improved con-
trol of viral hepatitis.
Conclusion
The burden of disease from viral hepatitis is large
and is projected to increase over the next several deca-
des. Cost-effective interventions (e.g., vaccination,
screening, and linking infected persons to quality care
Fig. 3. The chronic care model emphasizes the types of interac-
tions needed to support the health of those with chronic illness.
Table 3. Key Actions for Physicians and Other Health Care
Providers Toward Improved Control of Viral Hepatitis
 Educate self, staff, patients, care-givers, policy makers, and public
 Screen persons at risk of infection
 Counsel persons with chronic hepatitis to reduce secondary spread and to
reduce harm (e.g., alcohol use)
 Vaccinate susceptible persons against hepatitis A and B
 Monitor chronically infected persons for progression of liver disease or refer
for staging and consideration of antiviral therapy
 Perform HCC surveillance in chronically infected persons if indicated
 Eliminate health care–associated hepatitis transmission
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and treatment) can stop transmission, reduce disease
progression, and decrease the burden of liver disease;
however, many persons at risk for or are living with
viral hepatitis do not beneﬁt from these lifesaving
interventions because they are unaware of the risks,
have not been diagnosed, or have no access to care,
resulting in substantial health disparities. This status
quo is unacceptable and can be improved, particularly
in light of recent advances in laboratory testing, medi-
cal management and the approval of new antiviral
therapies. These interventions, coupled with innovative
public health education and testing strategies, can dra-
matically improve health outcomes. However, the suc-
cess of such an effort within the clinic and public
health setting will require enhanced coordination of
prevention and care services involving diverse compo-
nents of the health system. The AASLD–CDC Single-
Topic Conference on Viral Hepatitis served to pro-
mote this type of coordination.
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